Fulcrum Therapeutics, Inc. (FULC)

Market Cap	306.02M
Revenue (ttm)	2.62M
Net Income (ttm)	-98.71M
Shares Out	61.82M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	825,377
Open	5.04
Previous Close	4.95
Day's Range	4.45 - 5.12
52-Week Range	2.25 - 15.00
Beta	2.18
Analysts	Buy
Price Target	11.25 (+142.98%)
Earnings Date	Nov 7, 2023

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: FULC

Financial Performance

In 2022, FULC's revenue was $6.34 million, a decrease of -66.90% compared to the previous year's $19.16 million. Losses were -$109.87 million, 35.9% more than in 2021.

Analyst Forecast

According to 8 analysts, the average rating for FULC stock is "Buy." The 12-month stock price forecast is $11.25, which is an increase of 142.98% from the latest price.

Price Target

$11.25

(142.98% upside)

Analyst Consensus: Buy